The price of AxoGen Inc. (NASDAQ:AXGN) shares last traded on Wall Street rose 11.95% to $8.43.
Based on available information, 5 analysts follow AxoGen Inc. (NASDAQ:AXGN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $21.00 and a low of $13.00, we find $16.00. Given the previous closing price of $7.53, this indicates a potential upside of 112.48 percent. AXGN stock price is now -9.16% away from the 50-day moving average and -16.04% away from the 200-day moving average. The market capitalization of the company currently stands at $370.58M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Among analysts, 1 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $16.50 as their price target over the next twelve months.
On May 09, 2022, Canaccord Genuity Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $10 to quote $15, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’.
In other news, MARIANI PETER J, EVP & Chief Financial Officer sold 14,550 shares of the company’s stock on Feb 01. The stock was sold for $136,188 at an average price of $9.36. Upon completion of the transaction, the EVP & Chief Financial Officer now directly owns 61,945 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 31, EVP & Chief Financial Officer MARIANI PETER J sold 14,320 shares of the business’s stock. A total of $136,756 was realized by selling the stock at an average price of $9.55. This leaves the insider owning 55,555 shares of the company worth $0.47 million. Insiders disposed of 276,362 shares of company stock worth roughly $2.33 million over the past 1 year. A total of 3.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AXGN stock. A new stake in AxoGen Inc. shares was purchased by SWISS NATIONAL BANK during the first quarter worth $818,000. LEGATO CAPITAL MANAGEMENT LLC invested $720,000 in shares of AXGN during the first quarter. In the first quarter, HILLSDALE INVESTMENT MANAGEMENT INC. acquired a new stake in AxoGen Inc. valued at approximately $543,000. TWO SIGMA INVESTMENTS, LP acquired a new stake in AXGN for approximately $294,000. PRELUDE CAPITAL MANAGEMENT, LLC purchased a new stake in AXGN valued at around $215,000 in the second quarter. In total, there are 182 active investors with 80.00% ownership of the company’s stock.
A candlestick chart of AxoGen Inc. (NASDAQ: AXGN) showed a price of $7.35 on Tuesday morning. During the past 12 months, AxoGen Inc. has had a low of $6.87 and a high of $13.66. As of last week, the company has a debt-to-equity ratio of 0.45, a current ratio of 4.40, and a quick ratio of 3.50. The fifty day moving average price for AXGN is $9.24 and a two-hundred day moving average price translates $10.04 for the stock.
The latest earnings results from AxoGen Inc. (NASDAQ: AXGN) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.01, beating analysts’ expectations of -$0.12 by 0.11. This compares to -$0.17 EPS in the same period last year. The net profit margin was -21.50% and return on equity was -27.50% for AXGN. The company reported revenue of $36.96 million for the quarter, compared to $31.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.44 percent. For the current quarter, analysts expect AXGN to generate $36.21M in revenue.
AxoGen Inc.(AXGN) Company Profile
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
